Why did NCI transition its extramural pediatric brain tumor clinical trials to PEP-CTN?
Since 2019, NCI funded pediatric early-phase brain tumor clinical trials through two networks – the PBTC, comprised of 16 sites, and PEP-CTN, with 42 sites. In 2025, NCI made the decision to consolidate all trials into the larger PEP-CTN.
The PBTC made important contributions to the development and evaluation of new treatments for children with brain tumors, but enrollment had slowed in recent years. Through the larger PEP-CTN NCI believed a larger network of sites would accelerate enrollment.
What factors were considered in the transition to PEP-CTN?
The pediatric cancer research and clinical trial landscape has evolved substantially over 25 years.
- Pharmaceutical company involvement in early-phase clinical trials has increased, and additional academic consortia have been established to conduct clinical trials for children with brain tumors.
- NCI’s National Clinical Trials Network (NCTN), including COG, have greatly improved advances in clinical trial operations and data management.
Given this changing environment, NCI determined that, with additional resources and expanded pediatric neuro-oncology expertise, PEP-CTN could provide greater opportunities for children and families to participate in clinical research by conducting these trials across a larger network of sites.
The new PEP-CTN structure provides opportunities to draw on the significant expertise of pediatric neuro-oncologists who participated in PBTC while also engaging additional investigators, including members of the COG Central Nervous System (CNS) Tumor Committee.
Was this a cost-cutting measure?
No, the transition was not undertaken as a cost-cutting measure. Pediatric brain tumor research remains a high priority for NCI. NCI’s goal was to expand the number of sites and maximize the capabilities of the larger of its two similar networks to accrue patients faster and take advantage of the technology and data sharing resources of 42 sites as compared to 16 sites. NCI can leverage an established clinical trials infrastructure and complementary scientific expertise, reducing duplication of administrative and operational systems while directing resources toward scientifically promising research. A more robust and efficient infrastructure will better support the research itself.
NCI will continue evaluating the resources necessary to maintain a strong and effective pediatric brain tumor clinical trials program.
How are PBTC studies being transferred to PEP-CTN?
The transition is complete. Five PBTC studies that were active when the decision was made to transition have responsibly been transferred to PEP-CTN.
- Two PBTC trials for which accrual was too slow to allow successful completion were closed. Patients already enrolled on those studies were able to continue receiving protocol-specified treatment and follow-up through PEP-CTN.
- Three PBTC studies with strong scientific value and adequate accrual were transferred to PEP-CTN so that enrollment can be completed. These studies are planned to reopen to enrollment in late 2026 or early 2027.
In addition, a PBTC-developed clinical trial that had not yet opened to enrollment has been revised as a PEP-CTN clinical trial and is planned to open for enrollment in late 2026 or early 2027. A separate PBTC trial proposal that is still early in development is expected to result in a trial opening in mid-2027.
What happens to the data and protocols developed under PBTC?
NCI worked with PBTC leadership to incorporate the imaging data and associated clinical data of significant value into the NCI Childhood Cancer Data Initiative data ecosystem, making these data accessible for future research.